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Iron overload is a risk factor for diabetes. The link between iron and diabetes was first recognized in patho-
logic conditions—hereditary hemochromatosis and thalassemia—but high levels of dietary iron also impart
diabetes risk. Iron plays a direct and causal role in diabetes pathogenesis mediated both by b cell failure and
insulin resistance. Iron also regulates metabolism in most tissues involved in fuel homeostasis, with the
adipocyte in particular serving an iron-sensing role. The underlying molecular mechanisms mediating these
effects are numerous and incompletely understood but include oxidant stress and modulation of adipokines
and intracellular signal transduction pathways.Type 2 diabetes is a common and ever-increasing worldwide
health problem. Although well described in terms of its hallmarks
of insulin resistance and b cell failure, the proximal cause(s) of
type 2 diabetes and the mechanisms underlying its genetic
predisposition remain largely unknown. Plausible cases have
been made for the primacy of abnormalities in insulin signaling,
insulin secretion, activation of stress pathways, mitochondrial
dysfunction, hepatic fuel homeostasis, and central nervous
system regulation (reviewed in Hotamisligil, 2003; Kahn, 1998,
2003; Lowell and Shulman, 2005). It is well accepted that the
most reliable predictor for the disease is obesity; therefore,
much attention has also been paid to the contribution of nutrients
and nutrient-sensing pathways in situations of chronic caloric
excess. Most of the interest in the role of nutrients in diabetes
is centered on macronutrients, but a micronutrient, iron, is also
closely associated with diabetes risk in a number of hereditary
syndromes, as well as in common forms of type 2 diabetes.
Iron deficiency is also associated with obesity. In this review,
we will briefly summarize the control of iron homeostasis at the
levels of the organism and the cell and then review the evidence
that excess iron is associated with increased diabetes risk, that
this relationship is causal, and that excess iron even within the
‘‘normal’’ range has important detrimental effects on insulin
secretion, insulin sensitivity, adipokine levels, and metabolic
flexibility. Finally, we will consider the molecular mechanisms
for these relationships.
Iron Homeostasis
Iron plays an essential role as a cofactor for fuel oxidation and
electron transport, but it also has the potential to cause oxidative
damage if not carefully regulated, chaperoned, and, when in
excess, sequestered. Thus, extensive mechanisms to control
the uptake and fate of iron have evolved. The connections
between iron and metabolism are well established, particularly
in lower organisms. Iron entry into cells increases when needed
for fuel oxidation, and, conversely, the metabolic fate of glucose
and ethanol are dependent on the availability of iron. In Saccha-
romyces cerevisiae, both glucose exhaustion and iron limitation
trigger iron uptake signaled by Snf1 kinase, the yeast ortholog of
AMP-dependent kinase (AMPK) (Haurie et al., 2003). The SWI/
SNF chromatin-remodeling complex also controls the inductionof iron transport genes in S. pombe (Monahan et al., 2008). Thus,
in the shift from fermentative to respiratory glucose metabolism,
iron uptake is stimulated to allowmetallation of the enzymes and
electron carriers necessary for oxidative metabolism.
The regulation of iron metabolism has been extensively re-
viewed (Andrews and Schmidt, 2007; De Domenico et al.,
2008; Ganz, 2011; Hentze et al., 2010) and will be briefly summa-
rized here. This is a current summary of mechanisms and
pathways that are still being explored; many details and contro-
versies are not presented because of space constraints.
Most iron in mammalian organisms is recycled at a rate of
20–25 mg/day through the erythroid pool as macrophages
endocytose senescent erythrocytes. Roughly 5%–10% of that
amount per day is taken up through the intestine. Mammals do
not have the capacity to secrete excess iron in a regulated
fashion. In equilibrium, losses through sloughing of the intestinal
epithelium, death of other cells, and biliary excretion balance
intestinal uptake, but when uptake exceeds loss, excess iron is
sequestered intracellularly.
Because disposal of excess iron is usually a slow process in
humans, uptake of iron from the intestine is highly regulated
(Figure 1). In the duodenum, ferric iron (Fe3+) is first reduced to
ferrous iron (Fe2+) by the ferrireductase duodenal cytochrome
b (DCTB). Ferrous ions enter the cell through the divalent
metal-ion transporter 1 (DMT1 or SLC11A2). Iron exits the enter-
ocyte through the only known iron export channel, ferroportin
(FPN or SLC40A1). The iron is oxidized to Fe3+ by hephaestin
(HEPH), whereupon it binds to transferrin in the circulation.
Transferrin-bound iron can then be taken into cells by transferrin
receptors (TfRs), in most cells TfR1. A soluble form of the trans-
ferrin receptor bound to transferrin also exists, and its level in
serum is a sensitive indicator of functional iron deficiency
(Beguin, 2003).
TfR1 mediates iron uptake in most cells. Upon endocytosis,
the endosome is acidified and ferric iron is released from trans-
ferrin, reduced by the STEAP family of ferrireductases, and
enters the cytosol through DMT1, although this may not be the
exclusive transporter. Non-transferrin-bound iron can also enter
the cells directly through DMT1 and other transporters such as
Zip14 (Liuzzi et al., 2006; Mackenzie et al., 2006). The latter
mechanisms are likely to play a major role only when transferrinCell Metabolism 17, March 5, 2013 ª2013 Elsevier Inc. 329
Figure 1. Overview of Iron Trafficking
Intestinal free ferric (Fe3+) iron is reduced to Fe2+
by DCTB and enters the cell through the divalent
metal-ion transporter 1 (DMT1) and possibly other
carriers. Dietary heme is directly absorbed and
iron is released by heme oxygenase (HMOX). Iron
exits the enterocyte through the iron export
channel ferroportin (FPN). After oxidization by
hephaestin (HEPH), iron binds in the bloodstream
to transferrin (Tf), which binds to transferrin
receptors 1 and 2 (TfR1 and TfR2) on the surface of
target cells. Inmost cells, after endocytosis of TfR1
and acidification of the endosome, iron is released,
reduced by STEAP, and through DMT1 enters the
cytosol, where it is used (e.g., for heme or Fe-S-
cluster synthesis in the mitochondrion) or, if in
excess, sequestered by ferritin. Ferritin secreted
into the blood serves as a marker for tissue iron
stores. In the liver, Tf binds TfR2 and the protein
HFE, and, in concert with signaling via GPI-
anchored protein hemojuvelin (HJV), bone
morphogenic proteins (BMP) and the SMAD signal
transduction pathway, production of hepcidin is
signaled. Hepcidin induces internalization and
degradation of FPN, thus completing a negative
feedback regulatory loop.
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Most of the iron is used in the mitochondrion for heme and
iron-sulfur cluster synthesis, although its trafficking to the
mitochondrion for such utilization is incompletely understood.
Cytosolic iron levels are autoregulated through binding to iron-
regulatory proteins (IRPs). Excess iron releases IRPs from the
iron-responsive element (IRE) on the 30 untranslated region
(UTR) of the TFR1 messenger RNA (mRNA) and the 50 UTR of
the ferritin mRNA, as well as on the UTRs of mRNAs of several
other iron-regulated proteins. This results in decreased stability
of TfR mRNA, decreasing further iron uptake, and in increased
translation of ferritin, sequestering iron inside the cell. Part of
the increased ferritin that is translated is secreted, largely iron
free, and serves as a marker of tissue iron stores.
Transferrin-bound iron also interacts with the hepatocyte TfR2
and the protein HFE on the surface of hepatocytes (D’Alessio
et al., 2012). Through a signaling process that is still incompletely
understood but that also requires hemojuvelin (HJV), bone
morphogenic protein 6 (BMP6) (Andriopoulos et al., 2009;
Meynard et al., 2009), and the SMAD (human homolog of
Drosophila mad) pathway (Wang et al., 2005), the production
of hepcidin is stimulated. The involvement of TfR2, HJV, HFE,
and hepcidin in human iron homeostasis is demonstrated by
human mutations in all that result in iron overload. Hepcidin,
a 25 amino acid peptide, enters the systemic circulation and
induces internalization and degradation of intestinal epithelial
ferroportin, thus acting as a negative feedback regulator of iron
absorption (Nemeth et al., 2004). Hepcidin also regulates efflux330 Cell Metabolism 17, March 5, 2013 ª2013 Elsevier Inc.of iron from other cells that express high
levels of ferroportin, including macro-
phages. Although iron egress from the
enterocyte is the major control point for
entry of iron into the body, DMT1 is also
regulated by iron- and possibly hepci-
din-dependent mechanisms and by the
hypoxia-inducible transcription factorHIF-2a (Mastrogiannaki et al., 2009; Shah et al., 2009). Dietary
heme is also directly absorbed by the enterocyte through less
defined pathways (Shayeghi et al., 2005). Release of iron from
heme is accomplished by heme oxygenase (HMOX).
An important fact to consider in evaluating the effects of iron
on metabolism is the very wide range of ‘‘normal’’ serum ferritin
in humans, 30–300 ng/ml in men and 15–200 ng/ml in women
(Fleming et al., 2001; Nelson et al., 1978). The levels of very
few human blood constituents have such a 10-fold normal vari-
ation, suggesting the possibility that ‘‘normal’’ may not be ideal.
Despite the extensive regulation of iron uptake, it is possible with
dietary iron excess to achieve levels of tissue iron higher than are
necessary to maintain normal erythropoiesis and metabolic
function. Commercial ‘‘normal’’ rodent chows vary by a factor
greater than ten in iron content. More important than the abso-
lute levels of iron is its bioavailability, but when all factors are
considered, many normal chows deliver significantly higher
amounts of iron than are consumed by mice living in the wild
or are necessary to maintain normal breeding and blood
hemoglobin concentrations. The same is true of the diets of
many humans, particularly in affluent western cultures. Thus,
the results to be presented below suggest that within the bound-
aries of tissue iron levels defined by overt iron deficiency and
pathologic overload, the broad range of ‘‘normal’’ iron may, in
fact, include levels that confer health risks of which we are
currently unaware.
Iron homeostatic pathways are tightly linked to inflammatory
stressors. Inflammation causes significant upregulation of
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large increases in serum ferritin levels (reviewed in Ganz and
Nemeth, 2009). The fact that inflammation results in the suppres-
sion of intestinal iron uptake has been hypothesized to be related
to the beneficial effect of sequestering iron from invading
microbes. It may also be important in elucidating the link of
iron to diabetes that in turn is linked to inflammation (Hotamisligil,
2006). The relationships among diabetes, inflammation, and
ferritin, therefore, could be complex, with ferritin reflecting
excess iron stores that cause diabetes, reflecting inflammation
that causes diabetes, or both. Furthermore, if iron causes dia-
betes, one of the mechanisms could be through its ability to
cause oxidant stress that may be linked to inflammation. We
will first consider the evidence that suggests that iron overload
is sufficient to cause diabetes.
Diabetes Associated with Iron Overload in Pathologic
States: b Cell Failure and Insulin Sensitivity
The first and clearest evidence for a relation between iron and
human diabetes came from clinical observations of individuals
with pathologic iron overload. These included cases of heredi-
tary hemochromatosis (HH) (Buysschaert et al., 1997; Moirand
et al., 1997), as well as transfusional iron overload (Dmochowski
et al., 1993; Merkel et al., 1988). The best-studied example of
the latter is beta thalassemia major, although diabetes is also
a complication of other conditions requiring frequent or long-
term transfusion such as bone marrow transplantation (Baker
et al., 2007). Some rare causes of diabetes such as Friedreich
ataxia are also associated with disturbances of iron balance
and with mutations in proteins regulating iron metabolism
(Radisky et al., 1999). Below we describe the phenotypes of
these iron overload conditions.
Hereditary Hemochromatosis
HH is transmitted as an autosomal recessive trait and occurs in
approximately five per 1,000 Caucasians of northern European
descent (Pietrangelo, 2010). Most patients with hemochroma-
tosis are homozygous for a mutation in the HFE gene resulting
in the C282Y substitution in the HFE protein (Feder et al.,
1996). Mutations in TfR2, HJV, and hepcidin are rarer causes
of hemochromatosis (Pietrangelo, 2010). Normal HFE is partially
required for iron stimulation of hepcidin (Nemeth et al., 2005),
and in the absence of HFE, protein hepcidin expression is
reduced and iron absorption is inappropriately high for a given
body iron load (Nemeth et al., 2004). The high prevalence of
HFE mutations argues that it might have served an adaptive
function, preventing a restriction on iron uptake in populations
evolving in locations without consistent access to dietary iron
(Toomajian et al., 2003). HH was originally described as a triad
of diabetes, cirrhosis, and skin pigmentation. In relatively small
clinical studies not well controlled for selection bias, the preva-
lence of diabetes in hemochromatosis had been found to be
7%–40% (Buysschaert et al., 1997; Moirand et al., 1997). With
identification of the genetic cause of HH, however, it was
possible to perform more unbiased screens for diabetes preva-
lence. Recent studies show the prevalence of diabetes to be
13%–22% and impaired glucose tolerance 18%–30% (Hatunic
et al., 2010a; McClain et al., 2006). Of note, HH is largely
a disease of individuals of northern European descent, wherein
the background prevalence rate of diabetes is only 5%–10%.Other studies have not found increased diabetes prevalence in
C282Y homozygotes (Beutler et al., 2002), although in that
case comparing homozygotes to a control population that was
of mixed racial/ethnic descent might have skewed the baseline
diabetes prevalence.
The pathophysiology of diabetes associated with HH is
controversial, with evidence suggesting that both insulin defi-
ciency and insulin resistance are contributing factors (Hramiak
et al., 1997; Mendler et al., 1999). Some of this work is difficult
to interpret because subjects with established diabetes are
studied, in which case the attendant hyperglycemia might itself
have resulted in insulin resistance and insulin secretory abnor-
malities (Rossetti et al., 1990). In the authors’ study of this ques-
tion, when only HH subjects with prediabetes are considered,
those subjects differ significantly from controls only in terms of
insulin secretory capacity and in fact had a trend toward
increased insulin sensitivity (McClain et al., 2006). The subjects
with overt diabetes exhibit insulin resistance, but the great
majority of those individuals (80%) are also obese. One interpre-
tation of these data is that HH itself is diabetogenic mainly
because of decreased insulin secretion, and diabetes usually
results when insulin resistance from an independent mechanism
such as obesity intervenes. Individuals with HH cannot respond
with increased insulin secretion because of primary pathology
in the b cells, and therefore they are highly prone to develop
diabetes when insulin resistant (McClain et al., 2006). Consistent
with this hypothesis, insulin secretory abnormalities but not
insulin sensitivity improve when persons with HH undergo
phlebotomy (Abraham et al., 2006; Hatunic et al., 2010b).
Study of mouse models of HH, namely mice with targeted
deletion of Hfe or replacement of deleted wild-type Hfe with
a gene encoding the C282Y mutant, have contributed to our
understanding of the mechanisms involved in diabetes asso-
ciated with HH (Cooksey et al., 2004). Hfe/ mice exhibit
decreased insulin secretory capacity secondary to oxidative
stress, decreased glucose-stimulated insulin secretion, and
increased b cell apoptosis. These mice have increased insulin
sensitivity, however, and do not develop diabetes, supporting
the hypothesis that insulin resistance is a causal but secondary
factor in HH diabetes. Study of these mice has provided further
mechanistic insights. For example, the observed oxidative stress
in islets and other tissues is not only caused directly by the
generation of free radicals from iron reacting with hydrogen
peroxide (Fenton chemistry). In addition, iron interferes with the
trafficking of other transition metals. Mitochondrial uptake of
manganese (Mn2+) is inhibited, resulting in decreased metalla-
tion and activity of superoxide dismutase 2 (SOD2), and much
of the oxidant damage can be ameliorated by Mn supplementa-
tion (Jouihan et al., 2008). Thus, the effect of excess iron on
the levels and trafficking of other metals is an important but
understudied area.
Beta Thalassemia Major and Transfusional Iron
Overload
Thalassemia is a group of disorders characterized by deficient
production of the b globin subunit of hemoglobin (Weatherall,
1998). Patients with thalassemia become iron overloaded
because of the numerous transfusions required to maintain
adequate erythrocyte levels as well as from increased iron
absorption (Weatherall, 1998). A single unit of blood containsCell Metabolism 17, March 5, 2013 ª2013 Elsevier Inc. 331
Figure 2. Relative Risk of Diabetes as a Function of Ferritin or
Dietary Iron Intake in Four Studies
Plotted are the relative risks from four studies (Bowers et al., 2011; Qiu et al.,
2011; Ford andCogswell, 1999; Jiang et al., 2004), with the comparator groups
listed on the y axis.
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through the gut. The prevalence of diabetes in patients with
thalassemia is 6%–14% (Borgna-Pignatti et al., 2004; Vogiatzi
et al., 2009). Several studies have shown that insulin resistance
and insulin deficiency mark both the prediabetic state and dia-
betes in thalassemia (Dmochowski et al., 1993; Merkel et al.,
1988; Messina et al., 2002). Insulin secretory defects, however,
may appear earlier than insulin resistance (Jaruratanasirikul
et al., 2008). The existence of insulin sensitivity in HH but insulin
resistance in transfusional iron overload is probably explained
by the different tissues in which the excess iron accumulates
in situations of low hepcidin (HH) compared to high hepcidin
(thalassemia patients with iron overload). The causal role of
iron in the pathogenesis of diabetes is suggested by the
declining rates of diabetes since the more aggressive and wide-
spread use of iron chelation therapy (Borgna-Pignatti et al.,
1998; Gamberini et al., 2008).
Transfusions for other conditions are also associated with
increased diabetes risk. A relatively young cohort of survivors
of pediatric bone marrow transplantation, for example, had
a 5% prevalence of type 2 diabetes (Hoffmeister et al., 2004).
Another study revealed a prevalence of diabetes three times
that of sibling controls (Baker et al., 2007). Interpretation of
these studies is complicated, however, by the additional effects
of chemotherapeutic agents such as glucocorticoids and
asparaginase on insulin production and action.
Effects of Iron in Nonpathologic States: Diabetes
and Dietary Iron
Increased iron stores are also associated with the development
of typical type 2 diabetes (reviewed in Ferna´ndez-Real et al.,
2002a). For example, in 9,486 adults in the United States studied
as part of the National Health and Nutrition Education Survey
(NHANES), the odds ratios for newly diagnosed diabetes in
those with elevated serum ferritin levels are 4.94 for men and
3.61 for women (Ford and Cogswell, 1999). This iron-associated332 Cell Metabolism 17, March 5, 2013 ª2013 Elsevier Inc.risk approaches the relative risk engendered by obesity (Kriska
et al., 2003). Similar relationships between iron and diabetes
risk, insulin resistance, or both have emerged from studies of
other populations, including Europeans and African Americans
(Jiang et al., 2004; Tuomainen et al., 1997; Wilson et al., 2003),
and from other conditions, including gestational diabetes
(Afkhami-Ardekani and Rashidi, 2009) and prediabetes (Sharifi
et al., 2008). The strong relationship between ferritin and dia-
betes risk, across sexes and in different types of diabetes
(type 2 and gestational), even across the normal range of ferritin,
is evident in Figure 2 (Jiang et al., 2004). Recent data from the
NHANES population also demonstrate that high ferritin approxi-
mately doubles the risk for metabolic syndrome after accounting
for age, race, alcohol, smoking, and inflammatory state as
assessed by C-reactive protein (CRP) levels (Jehn et al., 2004).
High ferritin is also positively correlated with central adiposity
(Gillum, 2001; Iwasaki et al., 2005), hepatic steatohepatitis
(Dongiovanni et al., 2011), and cardiovascular disease (Iwasaki
et al., 2005; Qi et al., 2007).
Type 2 diabetes is a disease marked by chronic inflammation
(Hotamisligil, 2006), and ferritin increases with inflammation.
The question therefore arises whether high iron, whose best
biomarker is high ferritin, causes diabetes or diabetes causes
high ferritin. Several lines of evidence support the former
causality. In the study of metabolic syndrome quoted above,
for example, independent markers of inflammatory stress such
as CRP did not account for the association of ferritin with dia-
betes (Jehn et al., 2004). Other studies have also concluded
that the diabetes risk associated with high iron is not accounted
for by HH or inflammation but rather is related to dietary iron
overload (Fleming et al., 2001; Fleming et al., 2002). Two recent
studies of gestational diabetes have observed that the increased
risk is associated in particular with dietary heme iron, which is
more efficiently absorbed than nonheme iron (Bowers et al.,
2011; Qiu et al., 2011). The best evidence for the causality of
iron, however, is those studies in which reversal of diabetes
occurs with iron reduction (below).
Differences between the Diabetes Phenotype
of Hemochromatosis and Dietary or Transfusional
Iron Overload: Role of Adiponectin
An important dichotomy is evident when considering the pheno-
type of individuals with hemochromatosis compared to those
with typical type 2 diabetes. Namely, in both humans and in
the mouse models, prediabetic HH is associated with lower
insulin levels but enhanced insulin sensitivity (McClain et al.,
2006). The typical phenotype of subjects with type 2 diabetes
and those with dietary and transfusional iron overload, however,
is one of insulin resistance (Ferna´ndez-Real et al., 2002a).
Mouse models (Cooksey et al., 2004) and humans with HH
exhibit significantly higher levels of adiponectin (Gabrielsen
et al., 2012). Adiponectin is an adipokine, a secreted,
hormone-like protein produced by adipocytes and causally
linked to insulin sensitivity (Kubota et al., 2002). In contrast to
HH, mice with dietary iron overload have lower adiponectin
levels than mice on lower iron chows (Gabrielsen et al., 2012).
This finding is explained by the high ferroportin expression in
adipocytes (Gabrielsen et al., 2012). In the limited tissues
expressing high levels of ferroportin such as macrophages,
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expression, iron export, and, therefore, in decreased iron levels
despite total body iron overload (Brink et al., 1976; Cairo et al.,
1997; Knutson et al., 2005).
In dietary iron overload, by contrast, hepcidin levels rise and
iron accumulates in cells that express ferroportin, including
adipocytes, because ferroportin is downregulated. Thus, in
healthy non-HH populations, there is a negative relationship
between serum ferritin and adiponectin (Fargnoli et al., 2008;
Forouhi et al., 2007; Gabrielsen et al., 2012; Mojiminiyi et al.,
2008). A recent large study has also demonstrated not only
that ferritin is inversely associated with adiponectin, but also
that both of these markers are associated with adipocyte insulin
resistance as defined by elevated serum nonesterified fatty acid
levels despite elevated insulin (Wlazlo et al., 2013). Inflammation
increases ferritin and decreases adiponectin production (Sub-
auste and Burant, 2007), and adipose tissue is inflamed in
diabetes (Trayhurn and Wood, 2005), but this does not fully
account for the ferritin-adiponectin relationship. We have deter-
mined, for example, that normal-range serum ferritin levels are
strongly and inversely associated with adiponectin indepen-
dently of inflammation as assessed by serum levels of CRP,
IL-6, or tumor necrosis factor a (Gabrielsen et al., 2012). These
observations were made in large and independent cohorts of
subjects with type 2 diabetes and of obese subjects with dia-
betes compared to equally obese individuals without metabolic
syndrome. Ferritin predicts adiponectin levels significantly better
than body mass index. The relationship of ferritin to adiponectin
is weaker in females, probably because the range of ferritin
values is significantly narrower and lower in females than in
males. The data suggest that ferritin may be one determinant
of the higher adiponectin levels seen in females (Arita et al.,
1999) and provide a potential contributing reason for the
decreased incidence of diabetes in women prior to menopause
(Szmuilowicz et al., 2009).
The use by adipocytes of iron levels to regulate adiponectin
suggests an endocrine role for adipocytes in coordinating
organism-wide metabolic responses to iron availability, as they
do for responses to overall macronutrient status. There is other
evidence for crosstalk between iron and adipocyte metabolism.
Insulin treatment, for example, increases iron uptake by
increasing cell-surface expression of TfR1 in adipocytes (Davis
et al., 1986; Tanner and Lienhard, 1987). Iron induces lipolysis
in cultured adipocytes and modulates the lipolytic response
to norepinephrine (Rumberger et al., 2004; Yamagishi et al.,
2000). Adipocytes express not only common regulators of iron
homeostasis such as ferritin and iron-regulatory proteins (Festa
et al., 2000), but also iron-related proteins with restricted tissue
expression (TfR2, HFE, and hepcidin) (Bekri et al., 2006; Farahani
et al., 2004). In addition, expression of high levels of ferroportin
in adipocytes allows them to serve an iron-sensing function
with greater dynamic range and sensitivity, as reflected by
the blunting of adiponectin response to dietary iron in animals
with targeted deletion of the ferroportin gene in adipocytes
(Gabrielsen et al., 2012).
Reduction of Iron as a Treatment for Diabetes
The previous data lead to the prediction that decrease of iron
stores in dietary iron excess will be doubly beneficial to diabetesrisk, increasing both insulin secretion, as in the studies of HH,
and insulin sensitivity, through mechanisms that include
increasing adiponectin. The b cell will have similar response
and susceptibility to iron overload in both HH and dietary over-
load because of low or absent ferroportin (Hudson et al.,
2010). In addition, b cells may be especially sensitive to iron
because of high expression of DMT1 (Koch et al., 2003), which
is needed for import of zinc for secretory packaging, but can
also transport free serum iron whose levels will increase as
transferrin approaches higher levels of iron saturation. Beneficial
effects of phlebotomy have been demonstrated in a number
of animal models of type 2 diabetes. Otsuka Long-Evans
Tokushima Fatty (OLETF) rats that are phlebotomized or fed an
iron-deficient diet exhibit lower hemoglobin A1c levels than
controls (Minamiyama et al., 2010). Similar results are seen in
the leptin-deficient Ob/Ob model of type 2 diabetes wherein
low iron diets or iron chelators result in significant protection
from diabetes that is related both to increased insulin secretion
and sensitivity (Cooksey et al., 2010). In the latter study, the
effects of lowering iron are long lasting and reversible and,
importantly, are seen with levels of iron restriction that did not
result in iron-deficiency anemia. Supporting these observations,
iron-deficient veal calves and rats are more insulin sensitive than
are iron sufficient controls and exhibit increased glucose utiliza-
tion (Borel et al., 1993; Henderson et al., 1986; Hostettler-Allen
et al., 1993).
Somewhat surprisingly, human data on the effects of iron
depletion in common type 2 diabetes are scant. In relatively
small and short-term studies of non-HH subjects either with or
without known type 2 diabetes, phlebotomy improves insulin
sensitivity, insulin secretion, and glycemia (Facchini, 1998;
Ferna´ndez-Real et al., 2002b). Blood donors also exhibit
increased insulin sensitivity and secretion, although there might
be selection bias in these studies in terms of the population that
donates blood (Ferna´ndez-Real et al., 2005). The study on the
relation of iron to adiponectin, summarized in the previous
section, also included a proof-of-concept study of a very small
sample of prediabetic humans in which phlebotomy was
performed to bring the individuals from the highest quartile of
normal ferritin down to the lowest quartile (Gabrielsen et al.,
2012). This intervention improved adiponectin, the area under
the glucose curve, and the insulin disposition index, which is
the product of insulin secretion and insulin sensitivity and a useful
predictor of diabetes risk.
Phlebotomy also improves other factors associated with dia-
betes and the metabolic syndrome, including hypertriglyceride-
mia (Bofill et al., 1994), vascular reactivity (Ferna´ndez-Real et al.,
2002c), and markers of nonalcoholic steatohepatitis (NASH)
(Facchini et al., 2002). More recently, phlebotomy of 550–
800 ml blood (1–1.5 units) from individuals with metabolic
syndrome was shown to decrease blood pressure, fasting
glucose, HbA1c, and the ratio of LDL to HDL cholesterol when
measured 6 weeks after the first phlebotomy (Houschyar et al.,
2012). There was a trend toward an increase in insulin sensitivity
that was not significant (p = 0.28). As a cautionary note, however,
the individuals in the NASH study gained weight with blood
donation, and theOLETF rats on the iron deficient diet had higher
blood triglyceride and cholesterol levels (Minamiyama et al.,
2010). Both the weight gain and increased blood lipids areCell Metabolism 17, March 5, 2013 ª2013 Elsevier Inc. 333
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expenditure, and the phenotypes of those with overt iron defi-
ciency, to be described below. Larger and longer-term studies
are required in humans to address both the beneficial and poten-
tial adverse effects of iron depletion, their dose responsiveness,
and their longevity.
Iron, Obesity, and Lipid Metabolism
Most investigations into the effects of iron on metabolism have
focused on glucosemetabolism because of the important epide-
miologic connections between pathologic iron overload and
diabetes. These connections have been evident since the early
descriptions of hemochromatosis and its subsequent link to
tissue iron overload in the 19th century. There is evidence,
however, that iron also affects lipid metabolism, adipocyte
biology, and obesity. This is not surprising, given the effects of
iron on adiponectin, the requirement for iron in the oxidation of
lipids, and the potential additive effects of oxidative stress
from lipid metabolism and excess iron.
There is a greater prevalence of iron deficiency in obese (39%)
and overweight (12%) children and adolescents than normal
weight children whose prevalence of iron deficiency is only 4%
(Pinhas-Hamiel et al., 2003). The association of iron deficiency
with obesity has been confirmed in other populations that
include children and adults of both sexes (Cepeda-Lopez
et al., 2011; Yanoff et al., 2007). The immediate question that
arises is one of causality: the observations might simply be coin-
cidental; for example the diets of many obese individuals may be
enriched in iron-poor foods. Plausible cases for causality, in turn,
can be made in both directions: normal or high iron stores might
be needed to support higher rates of fatty acid oxidation so that
iron-deficient individuals are less able to mobilize and use high
fat, or, conversely, the inflammatory nature of obesity might
trigger increased hepcidin levels that limit dietary iron absorp-
tion. Support for the latter hypothesis comes from a study that
observed a 2-fold increase in the prevalence of iron deficiency
in obese Mexican women and children compared to lean
controls (Cepeda-Lopez et al., 2011). In this study, it was not die-
tary iron content but the inflammatory marker CRP, which was
higher in the obese group, that was the best predictor of iron
deficiency. Another study found body mass index to be associ-
ated with low serum iron but high ferritin, consistent with low-
grade inflammation in obesity causing iron sequestration,
perhaps mediated by hepcidin (Ausk and Ioannou, 2008). Other
studies have found patterns both of primary iron deficiency and
of inflammation-mediated iron sequestration in obese adults
(Yanoff et al., 2007). Thus, the iron phenotype of obese individ-
uals is likely heterogeneous.
Animal studies demonstrate that iron restriction can be
a primary and independent cause of adiposity. Namely, rats
fed an iron-deficient diet have increased fat mass, although there
is a compensating loss of lean mass such that obesity per se
does not develop (McClung et al., 2008). More recently, adipo-
cyte-restricted overexpression of the protein mitoNEET, which
sequesters iron sulfur clusters, was shown to lower adipocyte
heme and mitochondrial iron and result in extreme obesity in
Ob/Ob mice (Kusminski et al., 2012). The obesity, however, is
well tolerated, and the mice remain insulin sensitive and nondia-
betic. The phenotype is reminiscent of the ‘‘healthy obese’’334 Cell Metabolism 17, March 5, 2013 ª2013 Elsevier Inc.without metabolic syndrome who have lower ferritin levels that
those with metabolic syndrome (Gabrielsen et al., 2012). Other
studies have revealed further layers of complexity in the relation-
ship between iron and obesity; for example, an obesogenic high-
fat diet can cause decreased iron absorption in the gut, mediated
by dysregulation of the oxidoreductases DCTB and hephaestin
(Sonnweber et al., 2012).
The possible mechanisms underlying weight regulation by
iron are therefore likely to be multifactorial. Iron is required for
lipolysis in cultured adipocytes (Rumberger et al., 2004), and
this may contribute to the observations that rats fed an iron-
deficient diet (Stangl and Kirchgessner, 1998) and iron-deficient
women (Ozdemir et al., 2007) have lower plasma levels of
triglycerides. Another contributing factor to lower triglycerides
is that high levels of iron augment fatty acid oxidation, as was
shown in the HH mouse model (Hfe/) (Huang et al., 2011).
On normal chow, although Hfe/ mice exhibit increased
glucose uptake in skeletal muscle, glucose oxidation is de-
creased and the ratio of fatty acid to glucose oxidation is
increased. When put onto a high-fat diet, the Hfe/mice exhibit
increased fatty acid oxidation, are hypermetabolic, and are pro-
tected from obesity. In addition to promoting lipid oxidation, high
dietary iron also stimulates lipogenesis (Baquer et al., 1982), so
the net effects of iron on lipid metabolism are complex.
In addition to direct modulation of lipid metabolism pathways,
the finding that iron regulates adiponectin secretion suggests the
possibility that iron availability might also be used to coordinate
metabolism by regulating other hormones important to fuel and
energy homeostasis. Indeed, levels of the anorexigenic hormone
leptin are low in thalassemia patients (Chaliasos et al., 2010),
although this would be expected to contribute to greater caloric
intake, not leanness, in iron-overloaded individuals. The effects
of iron on adiponectin also cannot be simply reconciled with
the actions of iron to increase fatty acid oxidation rates, since
adiponectin promotes fatty acid oxidation but is decreased by
iron. The decrease in adiponectin could be seen as amechanism
to compensate for the fact that iron can stimulate fatty acid
oxidation directly (see below), thus protecting the organism
from additive oxidative stressors. Clearly much more basic
knowledge on the effects and mechanism of action of iron on
these diverse pathways in multiple tissues is needed before we
will understand the complex phenomena. Finally, an under-
standing of why both low and high iron are associated with
obesity is needed: is there a modal dose-response curve for
some of these effects, and are they related to independent and
distinct mechanisms at the two ends of the spectrum of tissue
iron levels?
Potential Molecular Mechanisms for Iron Regulation
of Glucose Metabolism
The mechanisms underlying the effects of altering tissue iron on
metabolism are just beginning to be understood. Given themany
effects in multiple tissues already described and the involvement
of iron and heme in processes as diverse as glucose and fat
oxidation, hypoxia sensing (Semenza, 2012), CO and NO
sensing, transcriptional regulation (Yin et al., 2007), generation
of reactive oxygen species, and regulation of hormone levels,
the effects of iron are likely to be protean. Furthermore, the
effects will have dose thresholds that will differ across the range
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excess.
Reactive Oxygen Species
Iron is capable of generating hydroxyl radicals fromperoxide and
can also inhibit antioxidant defenses such as SOD2 (Jouihan
et al., 2008), although it is worth noting that iron deficiency is
also associated with increased reactive oxygen species (ROS)
(Walter et al., 2002). High iron has been linked to oxidative
damage to DNA, lipids, and proteins that in turn has been impli-
cated in cardiovascular disease, diabetes, atherosclerosis, and
neurological degeneration as seen in Alzheimer’s (Jomova and
Valko, 2011). In the progression of diabetes ROS can cause
both b cell failure and insulin resistance. b cells are particularly
sensitive to ROS because of low expression of antioxidants
such as catalase and SOD2, overexpression of which have
been shown to increase b cell viability (Azevedo-Martins et al.,
2003; Lenzen et al., 1996). ROS can cause b cell dysfunction
by multiple mechanisms including decreased insulin gene
expression secondary to decreased expression of transcription
factors necessary for b cell differentiation, maintenance, and
insulin gene transcription (Kaneto et al., 2010). ROS have also
been reported to directly affect circulating human insulin by
hydroxylation of phenylalanine residues that results in lower
affinity binding to the insulin receptor (Montes-Cortes et al.,
2010). Finally, ROS can induce insulin resistance through
multiple mechanisms—for example, activation of FOXO1, which
prevents downregulation of gluconeogenesis even in the pres-
ence of insulin signaling (Ponugoti et al., 2012).
The number of other potential targets of ROS that could
contribute to diabetes is immense. It should be kept in mind
that low levels of ROS also act as physiologic and normal cell
signaling molecules that mediate cellular differentiation, survival,
and metabolism (Ray et al., 2012). In mammals, for example,
ROS generated by the electron transport complex III is released
into the intermembrane space of mitochondria, where it can
escape to the cytosol and activate PPARg, C/EBPa, and adipo-
cyte differentiation (Tormos et al., 2011). Other ROS signaling
targets include theMAPK and PI3K pathways, wherein oxidation
of cysteines in protein phosphatases results in activation (Ray
et al., 2012). Thus, ROS generated by intermediate levels of
iron may play a role in normal metabolic regulation, once again
emphasizing the theme that the transition between signaling
normal physiologic responses and pathophysiologic ones may
be a subtle one and that the effects of iron are likely to be highly
context dependent. Finally, it should be mentioned that iron is
also capable of generating reactive nitrogen species that are
also capable of triggering modification of macromolecules
(Nappi and Vass, 1998).
Hypoxia-Inducible Factors
Hypoxia-inducible factors 1 and 2 (HIF-1 and HIF-2) regulate
cellular response to low oxygen by upregulating transcription
of a diverse set of proteins involved in angiogenesis, erythropoi-
esis, and glycolytic flux (reviewed in Semenza, 2012). HIFs also
regulate iron metabolism, and under conditions of low iron
HIF-2 upregulates DMT-1 and DCYTB, while HIF-1 upregulates
DMT-1 and decreases ferritin (Romney et al., 2011; Shah et al.,
2009). Conversely, cellular iron levels regulate HIF protein levels
through control of prolyl hydroxylase (PHD) activity (Semenza,
2012). PHDs require iron and oxygen to hydroxylate HIF subunitsto target them for degradation by von Hippel-Lindau (VHL) E3
ubiquitin ligase. Under conditions of low iron or low oxygen,
PHDs are inactive andHIF is stabilized. As a result, b cells treated
with an iron chelator increase Hif1a protein, while iron treatment
decreases Hif1a (Cheng et al., 2010). Decreased Hif1a results in
downregulation of its targets, including the glucose transporters
Glut1 and Glut2, which in turn results in impaired glucose
sensing and glucose-stimulated insulin secretion (Cheng et al.,
2010). Mice with targeted deletion of Vhl in b cells develop basal
hypoglycemia with increased insulin. When challenged with
glucose, however, they have impaired glucose tolerance due
to impaired glucose stimulated insulin secretion (Zehetner
et al., 2008). The latter effect is explained by increased Hif-acti-
vated glucose uptake and glycolysis stimulating higher levels of
ATP production and insulin secretion in the basal state, whereas
with rising glucose there is less glucose oxidation resulting in
less ATP and insulin secretion than in normal cells.
HIFs are also known to regulate energy utilization in muscle,
liver, and fat by stimulating glycolysis and cellular glucose
uptake to allow for a shift to glycolytic metabolism. Specifically,
Hif-1a upregulates glucose transporters GLUT1 and GLUT3 and
increases expression of hexokinase 1 and 2 (Aragone´s et al.,
2009). Hypoxia impacts insulin signaling in adipocytes by
reducing the level of insulin receptor phosphorylation (Regazzetti
et al., 2009). HIF also plays a role of increasing the inflammatory
state of adipose tissue and increasing fibrosis through a HIF
target enzyme lysyl oxidase (Halberg et al., 2009). Targeted
disruption Hif-1a or Hif-1b in adipose tissue improves insulin
signaling and decreases fat mass even when the mice are
challenged with a high fat diet (Jiang et al., 2011). The integration
of these and other effects of hypoxia on metabolism is seen in
a disease of chronic pseudohypoxia, namely Chuvash poly-
cythemia. Patients with Chuvash polycythemia are homozygous
for a mutation in VHL that prevents HIF degradation, allowing
it to be constitutively active (Ang et al., 2002). These patients
have decreased circulating glucose, increased Glut1, and
decreased hemoglobin A1c (McClain et al., 2013).
AMP-Activated Protein Kinase
The AMP-activated protein kinase (AMPK) pathway controls
energy balance by sensing cellular energy status through its acti-
vation by an elevated ratio of AMP to ATP (Hardie, 2011). A large
variety of hormonal signals and metabolic stresses such as
glucose deprivation, ischemia, hypoxia, oxidative stress, and
hyperosmotic stress activate AMPK, although not all of these
work through altering the AMP:ATP ratio (Kahn et al., 2005).
Activated AMPK stimulates glucose uptake and fatty acid oxida-
tion in tissues and suppresses gluconeogenesis in liver (Long
and Zierath, 2006). These are pathways that play important
roles in the pathogenesis and treatment of diabetes and are
also pathways that are affected by iron. Close coregulation of
iron levels and metabolic parameters such as fuel preference is
conserved from yeast to mammals, and in yeast this coregula-
tion is mediated by the ortholog of AMPK, Snf1 (Haurie et al.,
2003; Shakoury-Elizeh et al., 2010).
As described above, Hfe/ mice demonstrate increased adi-
ponectin concentrations. One of the principal targets mediating
adiponectin action, AMPK, is activated in Hfe/ mice (Huang
et al., 2007), but iron can also activate AMPK independently of
adiponectin. Although the mechanism for this activation is notCell Metabolism 17, March 5, 2013 ª2013 Elsevier Inc. 335
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ations in AMP/ATP ratios caused by iron-induced mitochondrial
dysfunction (Jouihan et al., 2008), or (2) stimulation of the
upstream activating kinase of AMPK, LKB1, by SIRT1-mediated
deacetylation (Hou et al., 2008; Lan et al., 2008). SIRT1 is itself
activated by oxidant stress and/or NAD (Alcendor et al., 2007;
Brunet et al., 2004). These results serve further to illustrate the
complexity of the association of iron and diabetes risk in that
the effects of AMPK activation by iron on glucose disposal,
gluconeogenesis, and lipid oxidation are generally antidiabetic.
Thus, the integration of the pleiotropic effects of iron on diabetes
risk in multiple tissues is not yet fully understood.
Iron-Responsive Elements
IRPs maintain cellular iron homeostasis through iron-regulated
binding to IREs (reviewed in Anderson et al., 2012). IRP1 is
known to have dual functions, both as an iron sensor and as
a cytosolic aconitase when bound to iron sulfur clusters. In the
mitochondrion, aconitase functions in the tricarboxylic acid
(TCA) cycle, in which it catalyzes the reversible isomerization of
citrate and isocitrate, but in the cytosol the production of citrate
generates a substrate for ATP-citrate lyase. Cytosolic aconitase
is also important in reducing NADP+ to NADPH, a cofactor
for enzymes involved in synthesis of glutathione, lipids, and
cholesterol (Minard and McAlister-Henn, 2005). Mitochondrial
aconitase is sensitive to iron because it contains four iron sulfur
clusters and is downregulated by IRPs in low-iron conditions
(Eisenstein and Ross, 2003). Thus, not only do IRPs control
cellular iron metabolism but IRP-dependent regulation also has
far-reaching metabolic effects through control of mitochondrial
and cytosolic citrate levels. Abnormal IRP1 activity is seen in
patients with Friedreich ataxia (Condo` et al., 2010; Lobmayr
et al., 2005), a human degenerative neuromuscular disease
caused by a mutation in a mitochondrial protein, frataxin, which
is thought to be an iron chaperone or storage protein (Babcock
et al., 1997). In these patients, IRP1 aconitase activity is
decreased, while IRP binding to IREs is increased. Interestingly,
Friedreich ataxia is associated with increased prevalence of type
2 diabetes.
Epigenetic Effects of Iron
The Dutch Famine Birth Cohort Study’s finding of increased
prevalence of type 2 diabetes and metabolic syndrome in adults
prenatally exposed to extreme caloric restriction has prompted
investigations on the epigenetic impact of maternal nutrition on
the metabolic state of offspring (Ravelli et al., 1998). Maternal
iron intake impacts the metabolic programming of offspring,
although this relationship may be complex, with factors such
as the period of altered iron status and the direction of change
(high or low iron) affecting the phenotype. In rats, prenatal iron
deficiency increases susceptibility to high-fat-diet-induced
obesity, glucose intolerance, and hypertension (Bourque et al.,
2012). When not challenged with the high-fat diet, however,
offspring of rat dams with dietary iron restriction have improved
glucose tolerance and lower serum triglycerides although they
also demonstrate higher systolic blood pressure (Lewis et al.,
2001). Thus, the effects of iron on metabolic programming may
be diet dependent, consistent with its effects on mediators
such as AMPK. Human studies have also largely focused on
maternal iron deficiency, not iron excess, and not in the context
of diabetes risk. Anemia during the third trimester of pregnancy336 Cell Metabolism 17, March 5, 2013 ª2013 Elsevier Inc.lowers systolic pressure in 7-year-old offspring (Brion et al.,
2008). In contrast, iron supplementation in the first trimester
was associated with increased blood pressure in offspring
(Belfort et al., 2008). Collectively, these results indicate that die-
tary iron may be a factor in signaling the fed verse fasted state of
an organism, which could signal epigenetic modifications to
initiate an altered metabolic state that is compliant with nutri-
tional availability. More research is needed in this field to assess
the role of prenatal iron exposure in adult glucose homeostasis.
There are several possible mechanisms for iron control of
epigenetic modification including regulation of the sirtuin (Sirt)
family of histone deacetylases, the Jumonji C (JmjC)-domain-
containing histone demethylases, or both (reviewed in
Houtkooper et al., 2012; Takeuchi et al., 2006). Sirts couple
lysine deacetylation with NAD hydrolysis. Because NAD is
limiting for this reaction, it is one pathway through which metab-
olism can directly affect epigenetics. NAD can be recycled from
nicotinamide or synthesized de novo through a pathway rate-
limited by nicotinamide phosphoribosyltransferase (NAMPT,
also known as visfatin). There is a positive association between
circulating levels of NAMPT and levels of ferritin and prohepcidin
(Ferna´ndez-Real et al., 2007), although the physiologic
importance of circulating NAMPT is not fully understood, and
prohepcidin levels poorly reflect those of mature hepcidin.
Histone demethylation also affects gene expression in a manner
dependent on iron and the metabolic state of the cell. The JmjC-
domain family of demethylases removes mono- or dimethyl
groups through iron- and a-ketoglutarate-dependent oxidation
reactions. The importance of iron in this reaction is highlighted
by treatment of endothelial cells by desferoxamine, an iron
chelator, which decreases demethylase activity in Jmj-domain-
containing protein 6 to a similar level as protein knockdown
(Boeckel et al., 2011). Interestingly, deletion of JmjC-domain-
containing histone demethylase 2 (JHDM2a/) in mice leads
to obesity hyperlipidemia, hyperinsulinemia, and hyperleptine-
mia (Inagaki et al., 2009).
The mechanisms outlined in this section do not represent an
exhaustive catalog of all the pathways and mechanisms by
which iron may contribute to diabetes risk. For example, one
possible mediator of the effects of iron for which evidence is
emerging is heme, which is involved in several regulatory nodes.
For example,
d PGC-1a, a master transcriptional regulator of metabolic
programs also regulates heme synthesis (Handschin
et al., 2005; Yin et al., 2007);
d the regulation of circadian metabolic rhythm, disruption of
which is a risk factor for diabetes, is dependent on several
heme-containing proteins (Handschin et al., 2005; Yin
et al., 2007);
d and heme and iron play a role in microRNA processing
through regulation of Drosha/Pasha and Dicer microRNA
processing complexes (Faller et al., 2007; Li et al., 2012).
Iron is also linked to diabetes throughmitoNEET, an iron-sulfur
cluster protein and postulated target of the antidiabetic thiazoli-
dinediones (Colca et al., 2004; Wiley et al., 2007). Thiazolidine-
diones prevent mitochondrial iron accumulation, suggesting
that they may act, in part, through regulation of cellular iron
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tial for the multitude of pathways that require heme or iron sulfur
clusters for activity including the electron transport chain, TCA
cycle, and DNA repair (Rouault and Tong, 2009). These diverse
cellular processes illustrate that the relationship between iron
and metabolism is complex and more research is needed to
further establish how iron overload or depletion may affect these
pathways.Summary
Epidemiologic observations in humans and experimental studies
in animal models have established a clear association between
tissue iron stores and diabetes risk. A subset of these studies
suggests that the relation is causal, that is, high iron is sufficient
to cause diabetes. At the same time, it is clear that iron has
a multiplicity of effects in many tissues that can be either pro-
or antidiabetic at the ends of the spectrum that runs from iron
deficiency to iron excess. In the b cell, for example, excess
iron is toxic, but there is clearly also a minimum level required
for full metallation of the proteins needed for glucose oxidation
and glucose sensing. Likewise, although iron overload is associ-
atedwith diabetes risk, iron deficiency is associatedwith another
major risk factor for diabetes, obesity. The phenotypes of iron
excess and obesity are certainly not mutually exclusive,
however, and it might be in fact that the combination of obesity
and iron overload is particularly prone to causing diabetes
through its resulting combination of insulin deficiency and insulin
resistance. It is probably also the case that the full expression of
these effects depends on environmental and genetic factors. For
example, high iron-induced augmentation of fat oxidation may
be protective of obesity in individuals consuming diets with
modest fat content but may cause excessive oxidant stress
and concomitantly greater diabetes risk in individuals consuming
a high-fat diet. Clearly, much work is needed to address many
unanswered questions such as the following:
d Can long-lasting protection or cure of diabetes be afforded
to individuals with high iron, and, if so, what are optimal
levels of tissue iron and how may they be assessed?
d What is the effect of the full range of ‘‘normal’’ iron concen-
trations on diverse metabolic processes in tissues
including liver, fat, muscle, pancreas, gut, and brain?
d What are the molecular mechanisms for these effects and
can they be targeted by approaches other than changing
global iron levels?
d How might this knowledge be relevant to other diseases
with important components of both metabolism and redox
signaling/stress including cancer and neurodegenerative
diseases?
d Do the known polymorphisms in genes regulating iron
uptake, antioxidant defenses, and related regulatory path-
ways modify diabetes risk in humans?ACKNOWLEDGMENTS
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